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Abstract 
Renal denervation (RDN) is a therapy targeting treatment resistant hypertension (TRH). Symplicity 
HTN-1&2 reported response rates of >80%, however sham-controlled Symplicity HTN-3 failed to 
reach its primary blood pressure outcome. We address the current controversies surrounding RDN, 
illustrated with real-world data from two UK centres. 
In our cohort 52% of patients responded to RDN; 13 ± 32 mmHg reduction in office systolic BP (oSBP) 
at six months (n=29, p=0.03).  Baseline oSBP and number of ablations correlated with oSBP 
reduction (R=-0.47, p=0.01; R =-0.56, p=0.002).  
In our experience RDN is an effective treatment for some patients with TRH, however individual 
responses are highly variable. Selecting patients for RDN is challenging; only 10% (33/321) of 
patients screened were eligible for our study. Medication alterations and non-adherence confound 
outcomes. Adequate ablation is critical and should impact on future catheter design/training. 
Markers of procedural success and improved patient selection parameters remain key research 
aims.  
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Introduction  
Renal denervation (RDN) was developed as an endovascular ablation technique for patients with 
treatment resistant hypertension (TRH, blood pressure (BP) ≥140/90mmHg despite ≥3 anti-
hypertensive medications). The procedure uses various energy modalities (such as radiofrequency 
(RF), ultrasound or cryotherapy) to disrupt the nerves innervating the kidney including both 
sympathetic efferent and sensory afferent nerves(1); when activated the latter can trigger reflex 
increases in sympathetic activity and arterial pressure(2). Initial proof of concept and safety studies 
(Symplicity HTN-1 and EnligHTN I) and a subsequent randomised controlled trial (RCT, Symplicity 
HTN-2) reported response (≥10 mmHg drop in office systolic blood pressure (oSBP)) rates of ≥80% at 
6 months post RDN(3-5). Significant reductions in oBP were maintained out to at least 24 months 
post denervation in all three of these studies (-29/-14 mmHg, -29/-13 mmHg and -30/-11 mmHg 
respectively)(6-8). However, most recently, the American sham-RCT (Symplicity HTN-3) failed to 
meet its primary outcome of a reduction in office BP at 6 months, prompting renewed discussion 
into the efficacy of RDN(9). In this review we will address the current controversies surrounding RDN 
and consider how real-world RDN outcomes can be put into perspective in light of the data from 
these large scale studies. 
 
We will support this review with data from two UK centres, St Bartholomew’s Hospital in London 
(Bart’s) and the Bristol Heart Institute (BHI). These data illustrate the real-world clinical experience 
of RDN and highlight the variability in BP response, as well as some of the challenges involved in 
implementing a novel, invasive, irreversible and expensive therapy, in rigorously selected patients 
with TRH. The key findings from the cohort of our first 29 patients treated with RDN for TRH are 
described in Box 1; these lessons, which predict some of the problems that led to the failure of the 
large scale trial Symplicity HTN-3, will form the basis of our discussion.   
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Methods 
321 patients were screened in order to recruit 29 patients with TRH from two British Hypertension 
Society-accredited Specialist Hypertension Clinics (Bart’s: 11 patients, BHI: 18 patients) for RDN (see 
Figure 1). The subjects were enrolled between December 2009 and January 2011 in the Bart’s 
cohort, and March 2012 and January 2013 in the BHI cohort. Prior to RDN, our patients were 
investigated for secondary causes of hypertension, white-coat hypertension (home and/or 
ambulatory blood pressure monitoring (ABPM)) and questioned about drug adherence (with 
observed tablet taking and subsequent ABPM at Bart’s). Renal anatomy was determined prior to 
RDN using magnetic resonance or computerised tomography angiography and deemed suitable for 
ablation according to Joint British Society guidelines(10). RDN was performed via a 6 French femoral 
arterial sheath, under fluoroscopic guidance, using a Symplicity-Flex catheter (Medtronic, Inc., Santa 
Rosa, CA, USA). 4-7 discrete 8 watt RF ablations of 2 minutes duration each were administered 
within both renal arteries in a helical distribution. Patients were followed up with measures of office 
BP and ABPM at baseline, 1, 3, 6 and 12 months. The primary intent was to keep medications 
unchanged during follow-up, however medications could be changed at the discretion of the 
treating physician if clinically indicated. The study was approved by local ethics committees, and all 
patients provided written informed consent. 
 
Statistics 
Our data are presented as mean ± standard deviation. Changes in physiological parameters have 
been assessed for significance using Student’s t-test or 1-way ANOVA (with Bonferroni multiple 
comparison test) for continuous data with equal variances, Kruskal-Wallis test for continuous data 
with unequal variances, and Pearson chi-squared test for categorical data. Relationships between 
these parameters were evaluated using Pearson’s correlation coefficient and linear regression 
(GraphPad Prism). A two-tailed p value of <0.05 was regarded as statistically significant. 
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Results and Discussion 
 
Blood Pressure Outcomes 
The response rate in our cohort was only 52% (15/29) at 6 months and 62% (13/21) at 12 months 
post RDN.  Whilst there was a significant 13 ± 32 mmHg reduction in mean oSBP in our study cohort 
at six months following the procedure (n=29, p=0.03), this change is not of the magnitude seen in 
Symplicity HTN 1&2 (-22 ± 22 and -32 ± 23 mmHg respectively)(3, 5). Baseline patient characteristics 
for our cohort are summarised in Table 1 and mean oBP outcome data are shown in Figure 2.  The 
BP responses were highly variable with some patients developing a clinically significant (≥10 mmHg, 
n=15) reduction in oSBP 6 months post RDN, whilst in others little BP effect (n=7) or an increase 
(n=7) was observed. Amongst the 15 patients who did respond to RDN the oSBP reduction at 6 
months was robust (-38 ± 23 mmHg, p<0.05) and similar to that observed in Symplicity HTN-1&2(3, 
5), furthermore by 12 months four patients had an oSBP reduction of >50 mmHg. These individual 
data are shown in Figure 3.  
 
Our real-world data cannot replicate the findings of the Symplicity studies and are more reflective of 
the success rates seen in other European studies(11-13). The UK Renal Denervation Affiliation 
reports an oBP reduction of 22/9 mmHg (p<0.001) in a cohort of 246 patients from 16 centres (14). 
The ALSTER and Heidelberg registries also report real-world data, with better response rates of 76% 
(n=93) and 73% (n=63) respectively(15, 16). Persu et al. report a response rate of 59.6% in their 
meta-analysis of 10 European expert RDN centres(17), and the Global Symplicity Register of 998 
patients gives a response rate of 67%(18). These findings are more consistent with our 52% response 
rate and corroborate our clinical impression that whilst renal denervation is effective in some 
patients, it is not a panacea for all patients with poorly controlled hypertension. 
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13 patients in our cohort had ABPM data available at six months. There was a change in mean 24hr 
BP of -12 ± 21 / -7 ± 14 mmHg (p=0.07/0.10). Mean daytime BP changed by -14 ± 21 / -8 ± 14 mmHg 
(p=0.04/0.07) and mean night time BP by -9 ± 23 / -6 ± 15 mmHg (p=0.23/0.53)(Figure 4). The lack of 
ABPM data for all patients in our cohort is a clear limitation of the study. Our access to ABPM 
devices has now improved, however some patients (particularly those with the highest BP) continue 
to find high pressure cuff inflations during ABPM intolerable.  
 
Mahfoud et al. compared the reduction in office and ambulatory BP in patients with resistant and 
pseudo-resistant hypertension following RDN; whilst both groups demonstrated a reduction in oBP, 
only those with true resistant hypertension demonstrated a significant reduction in 24hr ABPM of -
10.2/-4.9 mmHg(19). The use of 24hr ABPM data as an outcome measure may also prove to better 
reflect the regression of end organ damage in these significantly hypertensive patients since 
nocturnal hypertension in particular correlates strongly with cardiovascular morbidity and 
mortality(20, 21).  Ultimately BP is only a surrogate marker for the physical and economic burden 
inflicted by conditions such as stroke, myocardial infarction and chronic kidney disease(19, 22). 
 
 
Predictors of Blood Pressure Response to Renal Denervation 
The strongest positive predictor for a reduction in oSBP in the Symplicity HTN-3 study was a baseline 
oSBP of ≥180 mmHg(9, 23), a criterion which has previously been shown to correlate with BP 
reduction post RDN, as highlighted in the Global Symplicity and Heidelberg registry data(16, 18). We 
confirmed this significant correlation between baseline oSBP and the change in oSBP at 6 months 
(R=-0.47, p=0.01, Figure 5A) in our subjects.  
 
Recent findings by Ewen et al. indicate that patients with isolated systolic hypertension (ISH) and 
therefore lower DBP, have a restricted response to RDN(24); this finding is supported by our data 
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with respect to baseline office and ambulatory DBP and ABPM outcomes (see figures 5B and C).  
 
Conventionally a BP response to RDN has been arbitrarily defined as a reduction in oSBP of 
≥10mmHg(3). If our cohort is divided into RDN BP responders (n=15, oSBP reduction ≥10mmHg), 
non-responders (n=7, change in BP -9 to +10 mmHg) and reverse responders (n=7, increase in oSBP 
>10 mmHg), the key significant differences in baseline characteristics between these groups relate to 
the number of ablations the participants received (see Table 2). Our data demonstrate a significant 
correlation between both the number of ablations per artery and the total number of ablations for 
any given patient and the reduction in oSBP at 6 months (R=-0.56, p=0.002 and R=-0.55, p=0.002 
respectively). 
 
 
RDN Technique 
One of the main critiques of Symplicity HTN-3 has been inadequate denervation due to operator 
inexperience/inadequate proctoring; there were 111 operators across 88 sites, of whom 31%  
contributed only 1 procedure and 23% contributed ≥5 procedures(9). This contrasts with the greater 
BP reductions seen in the Global Symplicity Registry in which 59% of operators performed >15 
procedures(18). Only 19/364 patients received per-protocol RDN in Symplicity HTN-3 and this, along 
with the confounding effects due to medication changes in 39% of the population, renders the trial 
difficult to interpret(9, 23). 
 
In our cohort, reverse responders had significantly fewer ablations than responders and non-
responders (see Table 2). It is possible that patients who only receive partial renal denervation may 
have an increase in BP due to unopposed action of the (usually inhibitory) reno-renal reflexes(25).  
Alternatively, partial denervation could cause sensitisation of those nerves that remain, 
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inflammation of the nerves, or growth of new nerves which could exacerbate the degree of 
hypertension(26, 27). 
 
So how much denervation is required? In Symplicity HTN-1 a subset of patients underwent 
assessment with norepinephrine spillover, a validated technique for assessing regional sympathetic 
tone(28); a 47% reduction in sympathetic nerve activity (SNA) appeared sufficient to achieve a 
reduction in BP(3, 29). Further analyses by Esler et al. have shown that denervation following renal 
nerve ablation is highly variable between individuals and it is clear that the procedure is far more 
technically challenging than previously considered(29, 30). When the Symplicity catheter was first 
launched, operators were advised to prioritise ablation of the proximal superior aspect of the renal 
artery in order to target the highest density of renal nerves.  However, review of novel anatomical 
human data indicates that the renal nerves accessible to intraluminal RF energy lie more distally in 
the renal artery adventitia(31); therefore operators following the earlier guidance may have been 
targeting the wrong part of the artery, resulting in inadequate denervation(32).  
 
If the ‘completeness’ of denervation relates to procedural success, then a method for assessing the 
degree of renal nerve disruption achieved would be of significant clinical benefit and guide 
development of evolving catheter technologies. Techniques including direct electrical renal nerve 
stimulation, urinalysis for breakdown products of renal sympathetic nerve degradation (e.g. tyrosine 
hydroxylase) and measurement of reflex responses to afferent renal nerve stimulation with agents 
such as adenosine or bradykinin are under evaluation(33-35).  
 
 
Patient Selection for Renal Denervation 
In Symplicity HTN-2, 109 out of 190 (56%) patients screened were eligible for RDN.  With tighter 
screening in Symplicity HTN-3 (including ABPM), of the 1441 patients assessed across 88 sites in the 
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United States, 561 (39%) were eligible for enrolment(5, 9). In our experience, meticulous screening 
of 321 patients referred to our Specialist Hypertension Clinics identified only 33 individuals (10%) 
with true TRH, suitable renal artery anatomy, and without significant excluding comorbidities 
(including eGFR <45 ml/min/1.73m2 as per Symplicity HTN-2(5)) who were eligible for RDN (see 
Figure 1 and Table 1). This is consistent with estimates that 10-15% of patients with hypertension 
are genuinely treatment resistant once secondary causes of hypertension, pseudo-resistant 
hypertension and poor medication adherence are excluded(36, 37).  
 
From our clinics, 184 of the 321 patients screened underwent renal magnetic resonance or 
computerised tomography (CT) angiography as part of their assessment for secondary hypertension; 
20% of these patients (36/184) were anatomically ineligible for RDN including 8 cases of renal artery 
stenosis. This is a slightly higher anatomical exclusion rate that the 16% (30/190) of patients with 
ineligible anatomy in Symplicity HTN-2, but of a similar magnitude to the 20% (179/880) anatomical 
exclusion rate in Symplicity HTN-3(5, 9).  
 
 
Medication Alteration and Adherence 
There are important limitations with both our cohort and the Symplicity HTN studies surrounding 
the confirmation of adherence to medications and also changes in antihypertensive medication 
during the follow-up period(3, 5, 9).  
 
In Symplicity HTN-2&3 there were medication changes in 23% and 39% of patients prior to 6 month 
follow-up respectively, however, the primary study outcomes were unaltered if patients with 
medication changes were removed from analyses(5, 9, 23). In our cohort, medications were changed 
in 59% (17/29) patients, however, there were no medication increases in patients who responded to 
RDN, and so, these drugs changes would have blunted, rather than supplemented, any BP effect 
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seen. The standardised stepped-care antihypertensive medication regime used in the DENER-HTN 
study demonstrates that this issue can be well managed, although adequate patient support and 
infrastructure is required(38).  
 
The run in period prior to RDN should also be considered; in Symplicity HTN-3 patients were only 
required to be on a stable drug regimen for two weeks prior to baseline assessments and it is 
therefore possible that medication changes could have influenced the data if there was an 
inadequate wash-in/wash-out period. An eight week period on stable medication should be required 
to ensure that any intervention is not confounded by a time-dependent drug effect(39). 
 
Symplicity HTN-3 did not simply show a failure to alter BP, it demonstrated a significant reduction in 
oSBP in both RDN and sham groups (-14.13±23.93 mmHg and -11.74±25.94 mmHg respectively (both 
p<0.001))(9). Of note, in Symplicity HTN-2 35% of control subjects had a ≥10 mmHg reduction in 
oSBP six months post RDN(5). This decrease in BP may be explained by an improvement in 
medication adherence. The phenomenon of a ‘placebo’ effect due to enrolment in a clinical study 
(also known as the Hawthorne effect) is well established(40) and it is likely that the 8 study contact 
points between screening and 6 month follow-up in Symplicity HTN-3 provided greater patient 
support than standard medical care(23). 
 
Kandazari et al. highlight the significant reduction in oSBP in RDN vs sham patients amongst non-
African American subjects in Symplicity HTN-3 (-15.2 vs -8.6 mmHg, p=0.01)(23). In fact, African 
American and non-African American subjects had similar oSBP responses 6 months after RDN (-15.5 
and -15.2 mmHg respectively), and the difference in the oSBP outcomes lies in the sham arm of the 
study(23). Amongst the sham group, African American participants demonstrated a borderline 
significant greater reduction in oSBP than non-African American subjects (-17.8 vs -8.6 mmHg, 
p=0.057)(23, 41). Flack et al.’s recent multivariate analysis of Symplicity HTN-3 demonstrated that 
13 
 
African American race did not independently predict SBP outcomes in either the RDN or sham 
groups, however, in the sham group the interaction between African American race and being 
prescribed at least one antihypertensive medication three times per day was associated with a 
greater reduction in oSBP at 6 months(41). In the sham group there was also a trend towards a 
greater reduction in oSBP for patients living in the south/south-eastern regions of the USA(41); areas 
which have previous been associated with lower rates of medication adherence(42).  
 
In Symplicity HTN-3 African American participants were taking a greater number of antihypertensive 
medications and had more complex medication regimes than non-African Americans(41). Individuals 
with complex drug regimens or who are prescribed a greater number of medications may be 
particularly likely to be non-adherent, and hence more vulnerable to a Hawthorne effect if enrolled 
in a clinical trial(43, 44). Hameed et al. addressed this issue by using directly observed medication 
administration with subsequent BP monitoring to confirm adherence prior to RDN(12). Their cohort 
achieved a response rate of 51% with an oBP reduction of -15/-6 mmHg (p=0.01/0.2) at 6 months, 
which is unlikely attributable to improved medication adherence. Given that at least 50% of patients 
with TRH are known to be non-adherent with their medications(45), more thorough assessment of 
medication adherence at screening, and during follow-up, should be mandatory in order to assess 
true drug resistance and establish any unreported changes in medication. Unfortunately, the best 
technique for assessing adherence, be it urine drug testing or observed tablet taking and ABPM, is 
yet to be established. 
 
 
Conclusions 
The failure of Symplicity HTN-3 to meet its primary BP outcome could condemn RDN to the history 
books. However, whilst individual responses vary considerably and real-world data cannot replicate 
the high success rates of earlier trials(18), and a Hawthorne effect amongst study participants must 
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be considered, there does appear to be a sub population of patients with TRH who respond to RDN. 
Whether this variability in outcome is due to inappropriate patient selection (including those with 
pseudo-resistant or non-sympathetically mediated hypertension), confounding drug titrations and 
adherence issues, or technical issues relating to incomplete denervation is yet to be clarified(46). 
Many of the controversies which now surround RDN could have been predicted from pre-existing 
real-world experience. The lessons detailed below (see Box 2) may help to identify those most likely 
to respond to RDN and evaluate the mechanisms underlying this intervention.  
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Box 1: Findings from the Bart’s/BHI renal denervation cohort. Following rigorous screening, 29 
patients underwent renal denervation using a Symplicity Flex catheter with baseline and outcome 
measures of office and ambulatory blood pressure. oSBP: office systolic blood pressure, RDN: renal 
denervation, TRH: treatment resistant hypertension. 
Real-world findings from the Bart’s/BHI renal denervation cohort 
1. Despite rigorous patient selection, using similar inclusion criteria, we could not 
reproduce the response rate of >80% seen in the first two Symplicity studies; the 
response rate in our cohort was only 52% at 6 months (n=29)(4,5). 
2. Baseline oSBP predicts an individual patient’s response (≥10 mmHg reduction in oSBP) to 
RDN; patients with an oSBP of >177 mmHg being most likely to respond.  
3. Previous studies have reported outcome data as a mean reduction in oBP, but this does 
not tell the full story.  The individual patient response to RDN is highly variable and 
responders, non-responders and even reverse responders (with an increase in oBP after 
RDN) can be identified. Reverse responders had fewer ablations points than both 
responders and non-responders in our cohort, a finding that highlights the importance of 
operator experience and has significant implications for the development of novel RDN 
catheters.  
4. Identifying appropriate patients for RDN is a challenge. From our specialist hypertension 
clinics, 321 patients were screened to identify only 33 (10 %) individuals with TRH who 
were eligible for RDN. 20% of these patients (36/184) were anatomically ineligible for 
RDN, including 8 cases of renal artery stenosis.  
5. Despite our aim to keep medications unchanged during the first six months of follow-up, 
17/29 (59%) patients had changes to their drug regimens during this period; challenges 
in controlling medications and confirming medication adherence in real-world clinical 
situations make BP outcome data more difficult to interpret. 
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Box 2. Clinical implications for future studies of renal denervation. RDN: renal denervation, oSBP: 
office systolic blood pressure, ABPM: ambulatory blood pressure monitoring.  
Clinical implications for future studies of renal denervation 
 The magnitude and rate of response to RDN in the real-world is not as high as in Symplicity 
HTN-1&2, and future trials should be powered accordingly. 
 ABPM at baseline and study endpoints should be mandatory, and the relationship 
between white-coat effect and response to RDN further addressed. 
 Blood pressure is a marker for hypertensive disease and data for hard endpoints based on 
target organ damage (e.g. left ventricular hypertrophy, excretory renal function, 
albuminuria, stroke, myocardial infarction) are required to support the efficacy of RDN. 
 RDN is consistently most effective in those patients with severe treatment resistant 
hypertension (oSBP >160 mmHg).  A greater understanding of the mechanisms underlying 
RDN should be established before this therapy is offered to the broader hypertensive 
population. 
 Hypertension is an umbrella term and may cover a range of pathologies.  Patients with 
white-coat effect or isolated systolic hypertension represent subgroups with different 
underlying physiology and therefore potentially different susceptibility to RDN. 
 Adequate ablation is critical and should impact on operator training and catheter design; 
BP outcomes can only be interpreted if we know that adequate denervation has been 
achieved. On-table markers of procedural success are required.  
 The extent of renal denervation required to reduce blood pressure is yet to be established, 
and the possibility that inadequate denervation could exacerbate hypertension must be 
considered. 
 Medication changes and adherence issues confound BP outcomes; every attempt should 
be made to standardise and monitor adherence to concurrent pharmacotherapy during 
RDN trials. 
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 Baseline   (n=29) 
Demographics  
Age (years) 55.4 ± 12.9 
Male gender 14  (48%) 
Body mass index (kg/m²) 30.2 ± 4.3 
Risk factors and target organ damage  
eGFR (ml/min/1.73m2) 74 ± 18 
Type II diabetes 5  (17%) 
Hypercholesterolaemia 7  (24%) 
Rheumatoid arthritis 2   (7%) 
Coronary artery disease 8  (28%) 
Cerebrovascular disease 9  (31%) 
Antihypertensive treatment  
No. of antihypertensive drugs 5.2 ± 1.7 
ACEi/ARB 23  (79%) 
Calcium channel blockers 21  (72%) 
Diuretics 22  (76%) 
Aldosterone antagonists 13  (45%) 
Beta-blockers 18  (62%) 
Alpha-blockers 18  (62%) 
Direct renin inhibitors 6  (21%) 
Centrally acting agents 12  (41%) 
Direct vasodilators 4  (14%) 
Office blood pressure and heart rate measurements  
SBP (mmHg) 188 ± 20 
DBP (mmHg) 104 ± 21 
PP (mmHg) 
Heart rate (bpm) 
84 ± 20 
82 ± 18 
ABPM Data   
Daytime SBP (mmHg, n=18) 171 ± 19 
Daytime DBP (mmHg, n=18) 101 ± 18 
Night time SBP (mmHg, n=16) 157 ± 23 
Night time DBP (mmHg, n=16) 89 ± 21 
24hr SBP (mmHg, n=16) 168 ± 19 
24hr DBP (mmHg, n=16) 99 ± 20 
24hr heart rate (bpm, n=16) 76 ± 12 
 
Table 1. Patient baseline characteristics. We present baseline demographic data for our cohort, 
including ABPM data excluding white-coat hypertension for 18/29 patients. The remaining 11 
patients were assessed for pseudo-resistant hypertension using home blood pressure monitoring or 
ABPM assessment in primary care prior to enrolment in our study. Data shown as mean ± standard 
deviation. eGFR: estimated glomerular filtration rate, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, PP: pulse pressure, ACEi: Angiotensin-converting enzyme inhibitors, ARB: 
Angiotensin receptor blockers, bpm: beats per minute. 
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Responders 
 (n=15) 
Non Responders 
 (n=7) 
Reverse 
Responders 
(n=7) 
P= 
Response to RDN  
at 6 months 
    
∆ oSBP -38 ± 23 [-49,-26]*† 1 ± 4.4 [-4.2,2.2]* 26 ± 10 [18,34]† <0.0001 
∆ oDBP -11 ± 19 [-20,-1] -3 ± 12 [-12,5] 5 ±16 [-6,17] 0.12 
Baseline Parameters     
Age (years) 59.9 ± 12.1 49.6 ± 9.0 51.4 ± 15.5 0.14 
Male gender 9  (60%) 3  (43%) 2  (29%) 0.37 
Body mass index (kg/m²) 29.7 ± 2.6 32.1 ± 5.1 29.8 ± 6.5 0.52 
eGFR (ml/min/1.73m2) 77 ± 13 72.4 ± 17.8 68.6 ± 25.9 0.55 
No. of antihypertensives 4.9 ± 1.6 5.9 ± 2.0 5.0 ± 1.8 0.49 
No. of ablations per artery 5.6 ± 0.6† 5.5 ± 0.8# 4.4 ± 0.8†# 0.003 
Total number of ablations 11.0 ± 1.2† 11.0 ± 1.5# 8.9 ± 1.7†# 0.008 
oSBP (mmHg) 192 ± 17 186 ± 14 180 ± 30 0.41 
oDBP (mmHg) 101 ± 21 105 ± 21 109 ± 24 0.69 
Heart rate (bpm) 79 ± 18 86 ± 17 90 ± 20 0.49 
 
 
Table 2. Difference in office BP outcomes and baseline parameters between BP responders 
(reduction in oSBP ≥10 mmHg), non-responders (change in oSBP between -9 and +10 mmHg) and 
reverse responders (increase in oSBP >10 mmHg). Significant differences between subgroups for 
each parameter as indicated (p<0.05): *Responders vs Non Responders, †Responders vs Reverse 
Responders, #Non Responders vs Reverse Responders. oSBP: office systolic blood pressure, oDBP: 
office diastolic blood pressure, bpm: beats per minute. Data shown as mean ± SD [CI]. P values from 
1 way ANOVA with Bonferroni multiple comparison test for continuous data and Pearson chi-
squared test for categorical data.  
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Figure 1. Patient screening pathway prior to renal denervation. All patients identified via Specialist 
Hypertension Clinic. eGFR; estimated glomerular filtration rate (units ml/min/1.73m2) 
 
Figure 2. Change in mean office systolic and diastolic blood pressure 1, 3, 6 and 12 months post 
renal denervation (RDN). SBP: systolic blood pressure, DBP: diastolic blood pressure. *p = 0.03, **p 
= 0.002. 
 
Figure 3. Change in office systolic blood pressure (oSBP) for individual patients at 1, 3, 6 and 12 
months post renal denervation (RDN). Patients grouped by oSBP outcome at 6 months post RDN: A. 
Responders (reduction in oSBP ≥10 mmHg), B. Non-responders (change in oSBP between -9 and +10 
mmHg), C. Reverse responders (increase in oSBP >10 mmHg). 
 
Figure 4. Change in blood pressure parameters for the 13 patients with ambulatory BP data at 
baseline and 6 months post renal denervation. SBP: systolic blood pressure, DBP: diastolic blood 
pressure. *p = 0.04 
 
Figure 5. A. Correlation between baseline office SBP and the change in office SBP (primary 
outcome measure) at 6 months post renal denervation.  In the 13 patients with available 
ambulatory BP data: B. Correlation between baseline office DBP and the change in mean 24hr SBP 
at 6 months post renal denervation, C. Correlation between baseline daytime DBP and the change 
in mean 24hr SBP at 6 months post renal denervation. oSBP: office systolic blood pressure, oDBP: 
office diastolic blood pressure, R: Pearson’s correlation coefficient. 
